Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Larnax GmbH
MediGene's recent licensing deal with Yamanouchi buys the German biotech time, but does little to strengthen its long-term finances. For this, MediGene will likely have to brave the cold waters of the German capital markets. It will be the first biotech to do so since Germany's growth market collapsed in 2001.
Summarizing the month in European dealmaking.